Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595586 | 0.87 | LMNA (0.54) | LMNAKCNH2ALDH1A1 | |
| SCHEMBL4532467 | 0.86 | LMNA (0.39) | LMNACYP3A4TSHRGAAKDM4E | |
| SCHEMBL4961500 | 0.79 | LMNA (0.47) | LMNAKCNH2MAPTMRGPRX4GSR | |
| SCHEMBL10595532 | 0.79 | LMNA (0.44) | LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14394483 | 0.79 | LMNA (0.47) | LMNAKCNH2 | |
| Hydrochloric Acid SCHEMBL10596067 | 0.78 | LMNA (0.43) | LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL18107068 | 0.77 | LMNA (0.45) | LMNAKCNH2 | |
| SCHEMBL4379609 | 0.76 | MRGPRX4 (0.54) | LMNATSHRKDM4EMRGPRX4 | |
| SCHEMBL26026438 | 0.74 | KCNH2 (0.41) | LMNACYP3A4TSHRGAAGRM2 | |
| SCHEMBL10596014 | 0.73 | ALDH1A1 (0.36) | LMNATSHRALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3473747-B1 | CHEMICAL PRECURSOR DELIVERY METHOD IN A DEPOSITION PROCESS | VERSUM MAT US LLC (US) | 2025-05-07 | — | — | EP | claimed |
| CN-114638484-B | Quality evaluation method for silk making process | 河北中烟工业有限责任公司 | 2024-12-20 | — | — | CN | claimed |
| CN-118668177-A | Hafnium oxide film and preparation method and application thereof | 大连恒坤新材料有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-116751174-A | Synthesis method of aryl substituted 1,3, 4-oxadiazole derivative | 铜陵欣诺科新材料有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-116362148-B | Method for calculating eddy current loss of rotor of high-speed permanent magnet motor | 湖南大学 | 2023-09-05 | — | — | CN | claimed |
| CN-114638484-A | Method for evaluating quality of silk making process | 河北中烟工业有限责任公司 | 2022-06-17 | — | — | CN | claimed |
| EP-0661973-B1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | CHILDRENS MEDICAL CENTER (US) | 2006-06-21 | — | — | EP | claimed |
| EP-0301424-B1 | SUSTAINED-RELEASE PERCUTANEOUS PREPARATIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | claimed |
| US-4889721-A | MULTILAYER; ADHESIVE LAYERS CONTAINING SOLID POLYMER | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-26 | — | — | US | claimed |
| EP-0100081-B1 | PYRIDYL ALKYL NITRATE COMPOUND, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-01 | — | — | EP | claimed |
| EP-0301424-A2 | Sustained-release percutaneous preparations | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-02-01 | — | — | EP | claimed |
| US-4749574-A | MICROCAPSULE OF 2-NITROXYMETHYL-6-CHLOROPYRINE OR ITS OCCLUSION COMPOUND WITH B-CYCLODEXTRIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-07 | — | — | US | claimed |
| EP-0241806-A1 | Sustained-release transdermal delivery preparations | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-21 | — | — | EP | claimed |
| CN-85102133-A | The occluded compound preparation method of 2-nitroxymethyl-6-chloropyridine and β-cyclodextrin | — | 1987-01-17 | — | — | CN | claimed |
| EP-0193164-A2 | Sustained-release pharmaceutical preparation which comprised 2-nitroxy-methyl-6-chloropyridine, process for its preparation and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-03 | — | — | EP | claimed |
| US-4575548-A | NONVOLATILE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-11 | — | — | US | claimed |
| US-4540701-A | 2-Nitroxymethyl and 2,6-bis-nitroxymethyl-pyridine compounds having vasodilating activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-09-10 | — | — | US | claimed |
| EP-0141300-A2 | An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-05-15 | — | — | EP | claimed |
| EP-0100081-A2 | Pyridyl alkyl nitrate compound, process for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-02-08 | — | — | EP | claimed |
| JP-60081166-A | — | — | None | — | — | JP | disclosed |
| JP-62000015-A | — | — | None | — | — | JP | disclosed |
| JP-60156607-A | — | — | None | — | — | JP | disclosed |
| JP-63045219-A | — | — | None | — | — | JP | disclosed |
| US-12631652-B2 | Methods of detecting markers for inflammatory conditions and food sensitivity in companion animals | VETICA LABS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260047199-A1 | LOGIC DRIVE USING STANDARD COMMODITY PROGRAMMABLE LOGIC IC CHIPS COMPRISING NON-VOLATILE RANDOM ACCESS MEMORY CELLS | ICOMETRUE CO LTD (TW) | 2026-02-12 | — | — | US | disclosed |
| CN-116751174-B | Synthesis method of aryl substituted 1,3, 4-oxadiazole derivative | 铜陵欣诺科新材料有限公司 | 2025-11-07 | — | — | CN | disclosed |
| US-12464820-B2 | Logic drive using standard commodity programmable logic IC chips comprising non-volatile random access memory cells | iCometrue Company Ltd. (TW) | 2025-11-04 | — | — | US | disclosed |
| EP-4180960-B1 | ERROR CORRECTION CIRCUIT AND ERROR CORRECTION METHOD | SAMSUNG ELECTRONICS CO LTD (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-20250273625-A1 | LOGIC DRIVE BASED ON MULTICHIP PACKAGE USING INTERCONNECTION BRIDGE | ICOMETRUE CO LTD (TW) | 2025-08-28 | — | — | US | disclosed |
| EP-3423830-B1 | METHODS OF DETECTING INFLAMMATORY MARKERS AND TREATING INFLAMMATORY CONDITIONS IN COMPANION ANIMALS | VETICA LABS INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250195463-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) | 2025-06-19 | — | — | US | disclosed |
| US-12327813-B2 | Logic drive based on multichip package using interconnection bridge | iCometrue Company (TW) | 2025-06-10 | — | — | US | disclosed |
| EP-3473747-B1 | CHEMICAL PRECURSOR DELIVERY METHOD IN A DEPOSITION PROCESS | VERSUM MAT US LLC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4543963-A1 | CYANATE ESTERS AS MONOMERS IN POLYMERISABLE COMPOSITIONS | Technische Universität Wien (AT) | 2025-04-30 | — | — | EP | disclosed |
| EP-4508058-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | Faculdade de Ciencias da Universidade de Lisboa (PT) | 2025-02-19 | — | — | EP | disclosed |
| US-12212339-B2 | Error correction circuit, memory system, and error correction method | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-01-28 | — | — | US | disclosed |
| CN-114638484-B | Quality evaluation method for silk making process | 河北中烟工业有限责任公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240340472-A1 | SATELLITE SWITCHING FOR ADDRESSABLE ASSET DELIVERY | COMERICA BANK | 2024-10-10 | — | — | US | disclosed |
| CN-118668177-A | Hafnium oxide film and preparation method and application thereof | 大连恒坤新材料有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240266322-A1 | LOGIC DRIVE BASED ON MULTICHIP PACKAGE USING INTERCONNECTION BRIDGE | ICOMETRUE CO LTD (TW) | 2024-08-08 | — | — | US | disclosed |
| US-12027491-B2 | Logic drive based on multichip package using interconnection bridge | iCometrue Company Ltd. (TW) | 2024-07-02 | — | — | US | disclosed |
| US-20240105729-A1 | LOGIC DRIVE USING STANDARD COMMODITY PROGRAMMABLE LOGIC IC CHIPS COMPRISING NON-VOLATILE RANDOM ACCESS MEMORY CELLS | iCometrue Company Ltd. (TW) | 2024-03-28 | — | — | US | disclosed |
| US-11881483-B2 | Logic drive using standard commodity programmable logic IC chips comprising non-volatile random access memory cells | iCometrue Company Ltd. (TW) | 2024-01-23 | — | — | US | disclosed |
| WO-2023247374-A1 | CYANATE ESTERS AS MONOMERS IN POLYMERISABLE COMPOSITIONS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2023-12-28 | — | — | WO | disclosed |
| CN-116970721-A | Primer probe combination for identifying and parting Chlamydia psittaci and application | 深圳市疾病预防控制中心 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023199134-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2023-10-19 | — | — | WO | disclosed |
| CN-116806436-A | Collaboration between mobile network operators of mobile edge computing applications | 华为技术有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230299774-A1 | LOGIC DRIVE USING STANDARD COMMODITY PROGRAMMABLE LOGIC IC CHIPS COMPRISING NON-VOLATILE RANDOM ACCESS MEMORY CELLS | iCometrue Company Ltd. (TW) | 2023-09-21 | — | — | US | disclosed |
| CN-116751174-A | Synthesis method of aryl substituted 1,3, 4-oxadiazole derivative | 铜陵欣诺科新材料有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116751174-A | Synthesis method of aryl substituted 1,3, 4-oxadiazole derivative | 铜陵欣诺科新材料有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116362148-B | Method for calculating eddy current loss of rotor of high-speed permanent magnet motor | 湖南大学 | 2023-09-05 | — | — | CN | disclosed |
| US-11750854-B2 | Satellite switching for addressable asset delivery | INVIDI TECHNOLOGIES CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11711082-B2 | Logic drive using standard commodity programmable logic IC chips comprising non-volatile random access memory cells | iCometrue Company Ltd. (TW) | 2023-07-25 | — | — | US | disclosed |
| EP-4180960-A1 | ERROR CORRECTION CIRCUIT, MEMORY SYSTEM, AND ERROR CORRECTION METHOD | Samsung Electronics Co., Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| CN-116110440-A | Error correction circuit, memory system and error correction method | 三星电子株式会社 | 2023-05-12 | — | — | CN | disclosed |
| US-20230146904-A1 | ERROR CORRECTION CIRCUIT, MEMORY SYSTEM, AND ERROR CORRECTION METHOD | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| CN-116071820-A | Weak supervision action detection method based on self-adaptive time sequence dropout mechanism | 同济大学 | 2023-05-05 | — | — | CN | disclosed |
| US-20220321128-A1 | LOGIC DRIVE USING STANDARD COMMODITY PROGRAMMABLE LOGIC IC CHIPS | iCometrue Company Ltd. (TW) | 2022-10-06 | — | — | US | disclosed |
| US-11408395-B2 | Method and device for detecting active power of wind turbine | BEIJING GOLDWIND SCIENCE & CREATION WINDPOWER EQUIPMENT CO., LTD. (CN) | 2022-08-09 | — | — | US | disclosed |
| US-11394386-B2 | Logic drive using standard commodity programmable logic IC chips | iCometrue Company Ltd. (TW) | 2022-07-19 | — | — | US | disclosed |
| US-20220223624-A1 | LOGIC DRIVE USING STANDARD COMMODITY PROGRAMMABLE LOGIC IC CHIPS COMPRISING NON-VOLATILE RANDOM ACCESS MEMORY CELLS | iCometrue Company Ltd. (TW) | 2022-07-14 | — | — | US | disclosed |
| EP-3521613-B1 | METHOD AND DEVICE FOR DETECTING ACTIVE POWER OF WIND POWER GENERATOR SET | BEIJING GOLDWIND SCIENCE & CREATION WINDPOWER EQUIPMENT CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| CN-114638484-A | Method for evaluating quality of silk making process | 河北中烟工业有限责任公司 | 2022-06-17 | — | — | CN | disclosed |
| US-11309334-B2 | Logic drive using standard commodity programmable logic IC chips comprising non-volatile random access memory cells | iCometrue Company Ltd. (TW) | 2022-04-19 | — | — | US | disclosed |
| US-20220029626-A1 | LOGIC DRIVE USING STANDARD COMMODITY PROGRAMMABLE LOGIC IC CHIPS COMPRISING NON-VOLATILE RANDOM ACCESS MEMORY CELLS | iCometrue Company Ltd. (TW) | 2022-01-27 | — | — | US | disclosed |
| US-20160206641-A1 | RAPIDLY-DISSOLVING THIN FILM FORMULATION OF WATER SOLUBLE DIGITALIS GLYCOSIDE FOR THE TREATMENT OF CONGESTIVE HEART DISEASE | LUMINUS BIOSCIENCES INC (US) | 2016-07-21 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| US-20070218121-A1 | Compounds that inhibit caspase activity for treating glaucoma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20060205679-A1 | Topical and oral formulations of cardiac glycosides for treating skin diseases | AZAYA THERAPEUTICS, INC. | 2006-09-14 | — | — | US | disclosed |
| EP-0661973-B1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | CHILDRENS MEDICAL CENTER (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050043225-A1 | Pharmaceutical formulation | SUPERGEN, INC. (US) | 2005-02-24 | — | — | US | disclosed |
| US-20050026849-A1 | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases | TRINITY LABORATORIES, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20040265369-A1 | Compounds that inhibit caspase activity for treating glaucoma | NIH-DEITR | 2004-12-30 | — | — | US | disclosed |
| US-20040254238-A1 | Bone growth stimulation with NO/statin and other NO modulating combinations | OSTEOSCREEN (US) | 2004-12-16 | — | — | US | disclosed |
| WO-2004091626-A1 | BONE GROWTH STIMULATION WITH NO/STATIN AND OTHER NO MODULATING COMBINATIONS | OSTEOSCREEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004087121-A2 | WATER SOLUBLE FORMULATIONS OF DIGITALIS GLYCOSIDES FOR TREATING CELL-PROLIFERATIVE AND OTHER DISEASES | AZAYA THERAPEUTICS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-0979073-A4 | NITROSYLATION TO INACTIVATE APOPTOTIC ENZYMES | CHILDRENS MEDICAL CENTER (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040014695-A1 | Mixture of cytolysis drug and cyclodextrin; side effect reduction; reducing ulcers | SUPERGEN, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6583125-B2 | Antiulceration effective amount of a substituted cyclodextrin compound and a cytotoxic drug, especially an anticancer drug; side effect reduction | SUPERGEN, INC. | 2003-06-24 | — | — | US | disclosed |
| US-20020106404-A1 | Compounds that inhibit caspase activity for treating glaucoma | NIH-DEITR | 2002-08-08 | — | — | US | disclosed |
| US-20020058634-A1 | Formulation of nitrogen mustard | SUPERGEN, INC. | 2002-05-16 | — | — | US | disclosed |
| EP-0717638-B1 | CYCLODEXTRINS FOR THE REDUCTION OF EXTRAVASATION TOXICITY CAUSED BY CYTOTOXIC COMPOUNDS | SUPERGEN INC (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6284747-B1 | MIXTURE OF CYCLODEXTRIN AND CYTOTOXIC AGENT | SUPERGEN, INC. | 2001-09-04 | — | — | US | disclosed |
| US-6218374-B1 | ADMINISTERING TO HOST, PREPARATION COMPRISING CYTOTOXIC COMPOUND THAT HAS POTENTIAL FOR CAUSING ULCERATION AND SUBSTITUTED CYCLODEXTRIN COMPOUND FOR REDUCING ULCERATION AND IRRITATION | SUPERGEN, INC. | 2001-04-17 | — | — | US | disclosed |
| US-6071876-A | ADMINISTERING TO A PATIENT A SUPEROXIDE DISMUTASE, OR SUPEROXIDE DIMUTASE MIMIC AND CATALASE TO ENHANCE CENTRAL NERVOUS SYSTEM ABSORPTION AND EFFICACY. | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2000-06-06 | — | — | US | disclosed |
| US-6048845-A | ANTIULCER AGENT; MIXTURE OF CYCLODEXTRI AD CYTOTOXIC DRUG | SUPERGEN, INC. (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0979073-A1 | NITROSYLATION TO INACTIVATE APOPTOTIC ENZYMES | The Children's Medical Center Corporation (US) | 2000-02-16 | — | — | EP | disclosed |
| EP-0661973-A4 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE. | CHILDRENS MEDICAL CENTER (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0581856-B1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | CHILDRENS MEDICAL CENTER (US) | 1999-07-14 | — | — | EP | disclosed |
| US-5824668-A | Formulation for administration of steroid compounds | SUPERGEN, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| WO-1998043621-A1 | NITROSYLATION TO INACTIVATE APOPTOTIC ENZYMES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-10-08 | — | — | WO | disclosed |
| EP-0866722-A1 | IMPROVED FORMULATION FOR ADMINISTRATION OF STEROID COMPOUNDS | Supergen, Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5804568-A | PARENTERAL ADMINISTRATION OF CYTOTOXIC DRUG MIXED WITH ANTIULCERATIVE AMOUNT OF SUBSTITUTED CYCLODEXTRIN; SIDE EFFECT REDUCTION | SUPERGEN, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5801203-A | Nitroglycerine patch | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-09-01 | — | — | US | disclosed |
| US-5747545-A | SCREENING COMPOUNDS BY DETERMINING CHANNEL BLOCKING TIME | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0327766-B1 | Redox systems for brain-targeted drug delivery | UNIV FLORIDA (US) | 1998-04-08 | — | — | EP | disclosed |
| EP-0481443-B1 | Transdermal therapeutic compositions | VECTORPHARMA INT (IT) | 1997-05-28 | — | — | EP | disclosed |
| WO-1997017992-A1 | IMPROVED FORMULATION FOR ADMINISTRATION OF STEROID COMPOUNDS | SUPERGEN, INC. (US) | 1997-05-22 | — | — | WO | disclosed |
| US-5602112-A | ANTI-ULCERATION AMOUNT OF SUBSTITUTED CYCLODEXTRIN, CYTOTOXIC ANTICANCER DRUG SOLUBLE IN AQUEOUS SOLUTION, SUGAR ALCOHOL | SUPERGEN, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| US-5582836-A | RIGID SUPPORTING SHEET WITH POLYMERIC FILM MATRIX SUSPENSION CONTAINING POROUS PARTICLES LOADED WITH DRUGS AND ABSORPTION PROMOTERS | VECTORPHARMA INTERNATIONAL S.P.A. (IT) | 1996-12-10 | — | — | US | disclosed |
| EP-0717638-A1 | IMPROVED PHARMACEUTICAL FORMULATION | SUPERGEN, INC. (US) | 1996-06-26 | — | — | EP | disclosed |
| EP-0519926-B1 | TRANSDERMAL SYSTEM | PHARMACIA AB REG NUMBER 556131 (SE) | 1996-05-01 | — | — | EP | disclosed |
| US-5455279-A | Regimen method of mediating neuronal damage using nitroglycerine | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0661973-A1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | The Children's Medical Center Corporation (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1995006485-A1 | IMPROVED PHARMACEUTICAL FORMULATION | SUPERGEN, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
| WO-1994006428-A1 | METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5234956-A | Method of preventing NMDA receptor complex-mediated neuronal damage | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0301424-B1 | SUSTAINED-RELEASE PERCUTANEOUS PREPARATIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0519926-A1 | TRANSDERMAL SYSTEM. | KABI PHARMACIA AB (SE) | 1992-12-30 | — | — | EP | disclosed |
| US-5120546-A | TRANSDERMAL SYSTEM | PHARMACIA AB (SE) | 1992-06-09 | — | — | US | disclosed |
| EP-0481443-A1 | Transdermal therapeutic compositions | VECTORPHARMA INTERNATIONAL S.P.A. (IT) | 1992-04-22 | — | — | EP | disclosed |
| WO-1991009592-A1 | TRANSDERMAL SYSTEM | KABI PHARMACIA AB (SE) | 1991-07-11 | — | — | WO | disclosed |
| EP-0168044-B1 | SUSTAINED RELEASE TABLET | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-06-05 | — | — | EP | disclosed |
| US-4889721-A | MULTILAYER; ADHESIVE LAYERS CONTAINING SOLID POLYMER | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| EP-0100081-B1 | PYRIDYL ALKYL NITRATE COMPOUND, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-01 | — | — | EP | disclosed |
| EP-0301424-A2 | Sustained-release percutaneous preparations | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-02-01 | — | — | EP | disclosed |
| US-4749574-A | MICROCAPSULE OF 2-NITROXYMETHYL-6-CHLOROPYRINE OR ITS OCCLUSION COMPOUND WITH B-CYCLODEXTRIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-07 | — | — | US | disclosed |
| US-4749574-A | MICROCAPSULE OF 2-NITROXYMETHYL-6-CHLOROPYRINE OR ITS OCCLUSION COMPOUND WITH B-CYCLODEXTRIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-07 | — | — | US | disclosed |
| JP-S6345219-A | SUSTAINED RELEASE PERCUTANEOUS ABSORPTION PREPARATION | FUJISAWA PHARMACEUT CO LTD | 1988-02-26 | — | — | JP | disclosed |
| EP-0241806-A1 | Sustained-release transdermal delivery preparations | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-21 | — | — | EP | disclosed |
| EP-0241806-A1 | Sustained-release transdermal delivery preparations | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-21 | — | — | EP | disclosed |
| US-4695467-A | STARCH DERIVATIVES, WATER SOLUBLE POLYMER | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-22 | — | — | US | disclosed |
| EP-0193164-A3 | SUSTAINED-RELEASE PHARMACEUTICAL PREPARATION WHICH COMPRISED 2-NITROXY-METHYL-6-CHLOROPYRIDINE, PROCESS FOR ITS PREPARATION AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-03 | — | — | EP | disclosed |
| EP-0193164-A3 | SUSTAINED-RELEASE PHARMACEUTICAL PREPARATION WHICH COMPRISED 2-NITROXY-METHYL-6-CHLOROPYRIDINE, PROCESS FOR ITS PREPARATION AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-03 | — | — | EP | disclosed |
| EP-0211079-A1 | SOFT MULTI-CHAMBER CAPSULE AND METHOD OF AND APPARATUS FOR MANUFACTURING SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-02-25 | — | — | EP | disclosed |
| CN-85102133-A | The occluded compound preparation method of 2-nitroxymethyl-6-chloropyridine and β-cyclodextrin | — | 1987-01-17 | — | — | CN | disclosed |
| CN-85102133-A | The occluded compound preparation method of 2-nitroxymethyl-6-chloropyridine and β-cyclodextrin | — | 1987-01-17 | — | — | CN | disclosed |
| CN-85102133-A | The occluded compound preparation method of 2-nitroxymethyl-6-chloropyridine and β-cyclodextrin | — | 1987-01-17 | — | — | CN | disclosed |
| JP-S6215-A | SUSTAINED RELEASE PHARMAEUTICAL CONTAINING 2-NITROXYMETHYL-6-CHLOROPYRIDINE OR CLATHRATE COMPOUND THEREOF IN BETA-CYCLODEXTRIN | FUJISAWA PHARMACEUT CO LTD | 1987-01-06 | — | — | JP | disclosed |
| US-4613608-A | CARDIOVASCULAR DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-23 | — | — | US | disclosed |
| EP-0193164-A2 | Sustained-release pharmaceutical preparation which comprised 2-nitroxy-methyl-6-chloropyridine, process for its preparation and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-03 | — | — | EP | disclosed |
| EP-0193164-A2 | Sustained-release pharmaceutical preparation which comprised 2-nitroxy-methyl-6-chloropyridine, process for its preparation and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-03 | — | — | EP | disclosed |
| EP-0193164-A2 | Sustained-release pharmaceutical preparation which comprised 2-nitroxy-methyl-6-chloropyridine, process for its preparation and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-09-03 | — | — | EP | disclosed |
| US-4575548-A | NONVOLATILE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-11 | — | — | US | disclosed |
| US-4575548-A | NONVOLATILE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-11 | — | — | US | disclosed |
| US-4575548-A | NONVOLATILE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-11 | — | — | US | disclosed |
| EP-0141300-A3 | AN OCCULUSION COMPOUND OF 2-NITROXYMETHYL-6-CHLOROPYRIDINE WITH BETA-CYCLODEXTRIN AND PROCESS FOR PREPARATION THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-29 | — | — | EP | disclosed |
| EP-0141300-A3 | AN OCCULUSION COMPOUND OF 2-NITROXYMETHYL-6-CHLOROPYRIDINE WITH BETA-CYCLODEXTRIN AND PROCESS FOR PREPARATION THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-29 | — | — | EP | disclosed |
| EP-0168044-A2 | Sustained release tablet | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-15 | — | — | EP | disclosed |
| US-4540701-A | 2-Nitroxymethyl and 2,6-bis-nitroxymethyl-pyridine compounds having vasodilating activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-09-10 | — | — | US | disclosed |
| JP-S60156607-A | PERCUTANEOUS ABSORPTION PHARMACEUTICAL CONTAINING 2- NITROXYMETHYL-6-CHLOROPYRIDINE OR BETA-CYCLODEXTRIN CLATHRATE COMPOUND THEREFOF | FUJISAWA PHARMACEUT CO LTD | 1985-08-16 | — | — | JP | disclosed |
| EP-0141300-A2 | An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-05-15 | — | — | EP | disclosed |
| EP-0141300-A2 | An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-05-15 | — | — | EP | disclosed |
| EP-0141300-A2 | An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-05-15 | — | — | EP | disclosed |
| JP-S6081166-A | BETA-CYCLODEXTRIN CLATHRATE COMPOUND OF 2-NITROXYMETHYL-6- CHLOROPYRIDINE AND PRODUCTION THEREOF | FUJISAWA PHARMACEUT CO LTD | 1985-05-09 | — | — | JP | disclosed |
| EP-0100081-A2 | Pyridyl alkyl nitrate compound, process for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-02-08 | — | — | EP | disclosed |
| EP-0100081-A2 | Pyridyl alkyl nitrate compound, process for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | LMNA 3003/4885CYP3A4 2764/4885TSHR 3708/4885 |
| US-12631652-B2 | Methods of detecting markers for inflammatory conditions and food sensitivity in companion animals | FCGR2A, FCGR1A, FABP2 | LMNA 4043/4885CYP3A4 3688/4885TSHR 2984/4885 |
| US-20060205679-A1 | Topical and oral formulations of cardiac glycosides for treating skin diseases | DSG1, PDIA5, NISCH | LMNA 863/4885CYP3A4 1529/4885TSHR 4741/4885 |
| US-20260047199-A1 | LOGIC DRIVE USING STANDARD COMMODITY PROGRAMMABLE LOGIC IC CHIPS COMPRISING NON-VOLATILE RANDOM ACCESS MEMORY CELLS | L1CAM, ICAM1, STIM1 | LMNA 1754/4885CYP3A4 4807/4885TSHR 1752/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | LMNA 3003/4885CYP3A4 2764/4885TSHR 3708/4885 |
| US-20250195463-A1 | ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE | SAMM50, CYP4F2, ABCB1 | LMNA 4866/4885CYP3A4 85/4885TSHR 3207/4885 |
| US-20050026849-A1 | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases | NISCH, CANX, DSC1 | LMNA 776/4885CYP3A4 2641/4885TSHR 4717/4885 |
| US-20040254238-A1 | Bone growth stimulation with NO/statin and other NO modulating combinations | NOS3, NOS1, NOS2 | LMNA 4158/4885CYP3A4 769/4885TSHR 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.